All In Biotech

BLA 761336 · Altor Bioscience, LLC, An Indirect Wholly-Owned Su

Anktiva

Nogapendekin Alfa Inbakicept-Pmln · Intravesical

Novel

CDER novel approval, Apr 22, 2024: To treat bladder cancer

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Apr 22, 2024

Approved uses

2

Original approval plus efficacy supplements

Registered trials

16

3 Phase 3, 5 recruiting

FAERS reports

49

23 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 27, 2026.

ANKTIVA, in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC). ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC). ( 1 )

Mechanism: Nogapendekin alfa inbakicept-pmln is an IL-15 receptor agonist. IL-15 signals through a heterotrimeric receptor that is composed of the common gamma chain (γc) subunit, the beta chain (βc) subunit, and the IL-15-specific alpha subunit, IL-15 receptor α. IL-15 is trans -presented by the IL-15 receptor α to the shared IL-2/IL-15 receptor (βc and γc) on the surface of CD4 + and CD8 + T cells and NK cells. Binding of nogapendekin alfa inbakicept-pmln to its receptor results in proliferation and activation of NK, CD8 + , and memory T cells without proliferation of immuno-suppressive Treg cells. In...

Therapeutic areas: Oncology · Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ANKTIVA · nogapendekin alfa inbakicept-pmln 400mcg/0.4 mL · SOLUTION, INTRAVESICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nogapendekin Alfa Inbakicept" as an intervention, any sponsor and status, largest first.

All 16 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • neutropenia10
  • chills7
  • pyrexia6
  • dysuria5
  • pollakiuria5
  • anaemia4
  • bladder pain4
  • nausea4
  • urinary tract infection4
  • drug ineffective3
  • haematuria3
  • abdominal distension2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202526
202623

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Anktiva (Nogapendekin Alfa Inbakic-PMln)

2024 spending

$2.9M

Beneficiaries

12

17 claims

Per beneficiary

$242,910

$89,966.84 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$2,914,926

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7 on PubMed

Sponsor: Altor Bioscience, LLC, An Indirect Wholly-Owned Su

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.